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The eukaryotic inward rectifier potassium 
(Kir) channel family is part of an ancient 
class of ion channels evolved in prokaryotes 
(Durell and Guy, 2001). Kir proteins have 
two transmembrane domains encompassing 
the pore loop region. Subunit tetrameriza-
tion, either homo- or hetero-typic, results in 
the formation of a functional channel. The 
16 known mammalian Kir channel proteins 
are divided over seven different families, 
each having their own specific expression 
pattern and functional characteristics (De 
Boer et al., 2010; Hibino et al., 2010). In gen-
eral, Kir channels allow more inward potas-
sium flow at membrane potentials negative 
from the potassium equilibrium potential 
(EK) than outward flow at equivalent mem-
brane potentials positive of EK, a character-
istic known as inward rectification. Within 
the superfamily, strong and weak rectifiers 
exist. Strong rectifying channels are most 
apparent in excitable tissues, where they are 
responsible for a stable and negative rest-
ing membrane potential, and due to their 
strong rectification, prevent extensive potas-
sium loss during action potential formation. 
Weak rectifiers are expressed in numerous 
other tissue types and organs and have a 
role in processes like potassium homeo-
stasis, insulin release, and signal transduc-
tion. Despite the long evolutionary history 
only a few inhibitors are known, of which 
most show limited specificity at their best. 
One of the most widely used Kir inhibitors 
is Ba2+. However, as it blocks all Kir chan-
nels at concentrations differing not even 
two orders of magnitude, its severe effects 
in whole animal studies or poisoning cases 
are difficult to ascribe to a given Kir family 
member (De Boer et al., 2010). Given the 
fact that most cell types express more than 
one Kir channel protein, lack of specific 
inhibitors therefore strongly hinders our 
understanding of their contribution and 
working mechanism in normal physiology 
and pathology. The presence of disease caus-
ing mutations in human Kir channels that 
lead to severe syndromes, e.g., Bartter’s syn-
drome (Kir1.1), Andersen Tawil syndrome 
(Kir2.1), SeSAME syndrome (Kir4.1), 
neonatal diabetes (Kir6.2), Snowflake vit-
reoretinal degeneration (Kir7.1) illustrate 
their importance in human pathology, 
while many more milder Kir related chan-
nelopathies probably remain unaccounted 
for at this moment. An excellent illustration 
of the potential of inward rectifier channel 
inhibitors comes from the field of neonatal 
diabetes where recognition of disease caus-
ing gain-of-function mutations in Kir6.2 
(Gloyn et al., 2004) and its regulatory subu-
nit Sur1 (Ellard et al., 2007) provided new 
insights to treat the disease with Kir6/Sur 
inhibitors (Pearson et al., 2006). One of the 
diseases that affects significant numbers of 
the aging human population, and has been 
correlated to Kir2.X and Kir3.X dysfunction, 
is atrial fibrillation. Increased Kir channel 
activity in the atria shortens atrial action 
potential durations and thereby allows 
formation of multiple re-entry circuits in 
the atrial tissue fueling rapid arrhythmia. 
Furthermore, ventricular Kir2.1 overex-
pression in mice results in rotor driven 
tachycardia’s. These mechanisms are likely 
to have a role in initiation and perpetuation 
of the process of atrial fibrillation. Therefore, 
pharmacological intervention by means of 
Kir channel modifying drugs may be a new 
and valuable treatment option in this disease 
(Ehrlich, 2008).
Standard single cell patch clamp meth-
ods allow highly detailed characterization 
of the inhibiting capacity and its underlying 
mechanisms of new compounds for virtu-
ally every ion channel of interest, including 
Kir channels. However, procedures are time 
consuming and therefore not compatible 
with large screening procedures. Automated 
patching techniques to a large extent over-
come these throughput limitations (Dunlop 
et al., 2008). Alternatively, the last decade, 
a number of non-electrophysiological Kir 
assay systems have been developed that allow 
large scale screening assays also. Systems are 
either based on membrane potential sen-
sitive dyes (e.g., Walsh, 2011) or thallium 
flux (e.g., Niswender et al., 2008). The latter 
makes use of a thallium sensitive fluores-
cent probe loaded into Kir expressing cells. 
Upon stimulation of channel opening, thal-
lium from the bath medium enters the cell 
through Kir channels, resulting in increased 
fluorescence. Co-application of different 
test compounds to the bath medium than 
enables identification of potent Kir channel 
inhibitors, and dependent on the assay con-
ditions, activators. New lead compounds for 
every Kir class will likely be derived from 
screening efforts of public, academic, or pri-
vate owned compound libraries (e.g., Wang 
et al., 2011), or from development of exist-
ing drugs displaying Kir channel block as an 
apparent side effect (Van der Heyden and 
Sánchez-Chapula, 2011).
In this issue of Frontiers in Pharmacology 
of Ion Channel and Channelopathies, 
Raphemot et al. (2011) describe the results 
from a screen for compounds that can 
inhibit Kir3.X channels. For this purpose, 
they used a thallium flux assay in combi-
nation with a compound library originally 
used for discovery of new Kir1.1 inhibitors. 
They identified a lead compound, named 
VU573 that besides blocking Kir3.X, also 
demonstrate specificity for Kir2.3 chan-
nels over Kir2.1. Subsequent cross valida-
tion using patch clamp assays in Xenopus 
oocytes and HEK293 cells reached similar 
conclusions. However, VU573 showed also 
inhibiting action on Kir7.1. Next, making 
clever use of a Kir7.1 mutant, they developed 
and validated a Kir7.1 thallium flux assay, 
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istry approach, this yielded a VU573 analog 
that lost affinity for Kir7.1 and Kir1.1, but 
retained reasonable inhibition of Kir3.X and 
Kir2.3. This makes an interesting combina-
tion from the perspective of atrial fibrillation 
therapy, since Kir3.1/3.4 and Kir2.3 are pre-
dicted channels involved in atrial fibrillation 
(Ehrlich, 2008) as mentioned before.
New questions are arising now. What 
is the nature of Kir inhibition by VU573? 
As pointed out by the authors, drugs can 
directly plug the channel pore inhibiting 
potassium flow, interfere with lipid [i.e., 
phosphatidylinositol 4,5-bisphosphate 
(PIP2)] dependent Kir activation or both. 
The preference of VU573 for Kir2.3 over 
Kir2.1 might indicate a role for PIP2 inter-
ference, but extensive studies using channel 
structure models, Kir mutations affecting 
PIP2 binding, and application of PIP2 during 
patch clamp experiments are required first 
to answer this intriguing question. Secondly, 
what is the long term effect of VU573 or 
its derivatives on ion channel trafficking? 
An increasing number of drugs, regardless 
whether they block the channel directly, 
affect channel protein trafficking result-
ing in decreased amounts of functional 
channels on the plasma membrane which 
may pose an arrhythmogenic risk (Van der 
Heyden et al., 2008). Thirdly, is a combined 
Kir3.X and Kir2.3 block effective indeed 
against atrial fibrillation without affecting 
ventricular electrophysiological parame-
ters? Dedicated in vitro and in vivo models 
are essential here to answers these questions.
The data reported by Raphemot et al. 
(2011) are another step in the development 
of subtype specific IK1 modifiers that even-
tually will provide valuable insights into 
the roles of IK1 in normal physiology and 
may offer clinicians new treatment options 
for a diverse set of genetic syndromes and 
acquired diseases.
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